Loading patent…
AssigneeUniversity of Virginia Patent Foundation
InventorsRahul Sharma, Mark D. Okusa
Estimating the term…
The present application discloses a novel fusion peptide of IL-2 and IL-33 and its use. It comprises a biologically active domain of Interleukin-2 (IL-2) or a biologically active fragment or homolog thereof, and a biologically active domain of Interleukin-33 (IL-33) or a biologically active fragment or homolog thereof. The two portions can be linked by a linker sequence. The application discloses that combination therapies using IL-2 and IL-33 or a therapy using the IL233 fusion protein are effective in preventing or treating diseases and disorders such as autoimmune diseases and disorders, inflammation, etc. Depending on the subject's disease or disorder, the compositions of the invention are useful for preventing certain symptoms, treating the disease, and alleviating at least some of the symptoms.
An Interleukin-233 (IL233) fusion protein comprising a biologically active domain of Interleukin-2 (IL-2) or a biologically active fragment thereof, wherein said domain binds with the IL-2 receptor, and a biologically active domain of Interleukin-33 (IL-33) or a biologically active fragment thereof, wherein said IL-33 domain binds with the IL-33 receptor, further wherein said IL-2 domain is linked to said IL-33 domain with a linker sequence of SEQ ID NO:5, and the fusion protein comprises the amino acid sequences of SEQ ID NO:2 or SEQ ID NO:11.
2-3. (canceled)
(canceled)
(canceled)
16-34. (canceled)
37-38. (canceled)
41-44. (canceled)
46-47. (canceled)
49-50. (canceled)
(canceled)
Dependencies are inferred from the claim text.